We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Kinesin Like Protein KIF11 (Kinesin Like Protein 1 or Kinesin Like Spindle Protein HKSP or Kinesin Related Motor Protein Eg5 or Thyroid Receptor Interacting Protein 5 or TRIP5 or EG5 or KIF11) - Pipeline Review, H2 2018

Published: September 2018
Pages: 58
Code: DA31C385B2FF414FE5F1F512D5188AF3
Format: PDF
Publisher Global Markets Direct
From Add to basket
$ 3,500.00
According to the recently published report 'Kinesin Like Protein KIF11 - Pipeline Review, H2 2018'; Kinesin Like Protein KIF11 (Kinesin Like Protein 1 or Kinesin Like Spindle Protein HKSP or Kinesin Related Motor Protein Eg5 or Thyroid Receptor Interacting Protein 5 or TRIP5 or EG5 or KIF11) pipeline Target constitutes close to 6 molecules. Out of which approximately 4 molecules are developed by companies and remaining by the universities/institutes.
Kinesin Like Protein KIF11 (Kinesin Like Protein 1 or Kinesin Like Spindle Protein HKSP or Kinesin Related Motor Protein Eg5 or Thyroid Receptor Interacting Protein 5 or TRIP5 or EG5 or KIF11) - Kinesin spindle protein (KSP) is a member of the kinesin superfamily of microtubule-based motors. It plays an important role in mitosis. It mediates centrosome separation and bipolar spindle assembly and maintenance. Inhibition of KSP function leads to cell cycle arrest at mitosis with the formation of monoastral microtubule arrays and ultimately cell death.
The report 'Kinesin Like Protein KIF11 - Pipeline Review, H2 2018' outlays comprehensive information on the Kinesin Like Protein KIF11 (Kinesin Like Protein 1 or Kinesin Like Spindle Protein HKSP or Kinesin Related Motor Protein Eg5 or Thyroid Receptor Interacting Protein 5 or TRIP5 or EG5 or KIF11) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Kinesin Like Protein KIF11 (Kinesin Like Protein 1 or Kinesin Like Spindle Protein HKSP or Kinesin Related Motor Protein Eg5 or Thyroid Receptor Interacting Protein 5 or TRIP5 or EG5 or KIF11) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase I and Preclinical stages are 2 and 2 respectively. Similarly, the universities portfolio in Discovery stages comprises 2 molecules, respectively.
Report covers products from therapy areas Oncology which include indications Ovarian Cancer, Bladder Cancer, Breast Cancer, Colorectal Cancer, Head And Neck Cancer, Hepatocellular Carcinoma, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Kidney Cancer (Renal Cell Cancer), Liver Cancer, Lung Cancer, Lymphoma, Melanoma, Multiple Myeloma (Kahler Disease) and Non-Small Cell Lung Cancer.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Additonal Information

  • - The report provides a snapshot of the global therapeutic landscape for Kinesin Like Protein KIF11 (Kinesin Like Protein 1 or Kinesin Like Spindle Protein HKSP or Kinesin Related Motor Protein Eg5 or Thyroid Receptor Interacting Protein 5 or TRIP5 or EG5 or KIF11)
  • - The report reviews Kinesin Like Protein KIF11 (Kinesin Like Protein 1 or Kinesin Like Spindle Protein HKSP or Kinesin Related Motor Protein Eg5 or Thyroid Receptor Interacting Protein 5 or TRIP5 or EG5 or KIF11) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • - The report reviews key players involved in Kinesin Like Protein KIF11 (Kinesin Like Protein 1 or Kinesin Like Spindle Protein HKSP or Kinesin Related Motor Protein Eg5 or Thyroid Receptor Interacting Protein 5 or TRIP5 or EG5 or KIF11) targeted therapeutics and enlists all their major and minor projects
  • - The report assesses Kinesin Like Protein KIF11 (Kinesin Like Protein 1 or Kinesin Like Spindle Protein HKSP or Kinesin Related Motor Protein Eg5 or Thyroid Receptor Interacting Protein 5 or TRIP5 or EG5 or KIF11) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • - The report summarizes all the dormant and discontinued pipeline projects
  • - The report reviews latest news and deals related to Kinesin Like Protein KIF11 (Kinesin Like Protein 1 or Kinesin Like Spindle Protein HKSP or Kinesin Related Motor Protein Eg5 or Thyroid Receptor Interacting Protein 5 or TRIP5 or EG5 or KIF11) targeted therapeutics

Companies Mentioned

4SC AG
Alnylam Pharmaceuticals Inc
Kyowa Hakko Kirin Co Ltd
Merck & Co Inc

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage Identify and understand the targeted therapy areas and indications for Kinesin Like Protein KIF11 (Kinesin Like Protein 1 or Kinesin Like Spindle Protein HKSP or Kinesin Related Motor Protein Eg5 or Thyroid Receptor Interacting Protein 5 or TRIP5 or EG5 or KIF11) Identify the use of drugs for target identification and drug repurposing Identify potential new clients or partners in the target demographic Develop strategic initiatives by understanding the focus areas of leading companies Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Kinesin Like Protein KIF11 (Kinesin Like Protein 1 or Kinesin Like Spindle Protein HKSP or Kinesin Related Motor Protein Eg5 or Thyroid Receptor Interacting Protein 5 or TRIP5 or EG5 or KIF11) development landscape Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Add to basket
  • Table of Contents
  • List of Tables
  • List of Figures
  • Introduction
  • Global Markets Direct Report Coverage
  • Kinesin Like Protein KIF11 (Kinesin Like Protein 1 or Kinesin Like Spindle Protein HKSP or Kinesin Related Motor Protein Eg5 or Thyroid Receptor Interacting Protein 5 or TRIP5 or EG5 or KIF11) - Overview
  • Kinesin Like Protein KIF11 (Kinesin Like Protein 1 or Kinesin Like Spindle Protein HKSP or Kinesin Related Motor Protein Eg5 or Thyroid Receptor Interacting Protein 5 or TRIP5 or EG5 or KIF11) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Kinesin Like Protein KIF11 (Kinesin Like Protein 1 or Kinesin Like Spindle Protein HKSP or Kinesin Related Motor Protein Eg5 or Thyroid Receptor Interacting Protein 5 or TRIP5 or EG5 or KIF11) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Kinesin Like Protein KIF11 (Kinesin Like Protein 1 or Kinesin Like Spindle Protein HKSP or Kinesin Related Motor Protein Eg5 or Thyroid Receptor Interacting Protein 5 or TRIP5 or EG5 or KIF11) - Companies Involved in Therapeutics Development
  • 4SC AG
  • Alnylam Pharmaceuticals Inc
  • Kyowa Hakko Kirin Co Ltd
  • Merck & Co Inc
  • Kinesin Like Protein KIF11 (Kinesin Like Protein 1 or Kinesin Like Spindle Protein HKSP or Kinesin Related Motor Protein Eg5 or Thyroid Receptor Interacting Protein 5 or TRIP5 or EG5 or KIF11) - Drug Profiles
  • 4SC-205 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ALN-VSP - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • MK-8267 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit KSP for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit Mitotic Kinesin Eg5 for Ovarian Cancer - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SRI-35566 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Kinesin Like Protein KIF11 (Kinesin Like Protein 1 or Kinesin Like Spindle Protein HKSP or Kinesin Related Motor Protein Eg5 or Thyroid Receptor Interacting Protein 5 or TRIP5 or EG5 or KIF11) - Dormant Products
  • Kinesin Like Protein KIF11 (Kinesin Like Protein 1 or Kinesin Like Spindle Protein HKSP or Kinesin Related Motor Protein Eg5 or Thyroid Receptor Interacting Protein 5 or TRIP5 or EG5 or KIF11) - Discontinued Products
  • Kinesin Like Protein KIF11 (Kinesin Like Protein 1 or Kinesin Like Spindle Protein HKSP or Kinesin Related Motor Protein Eg5 or Thyroid Receptor Interacting Protein 5 or TRIP5 or EG5 or KIF11) - Product Development Milestones
  • Featured News & Press Releases
  • Jun 03, 2015: 4SC Presents Final Results From Phase I AEGIS Trial As Well As Rationale For Daily Dosing Scheme Of 4SC-205 Cancer Compound At ASCO
  • Dec 09, 2014: 4SC reports positive top line data from clinical Phase I trial with 4SC-205 in cancer patients using novel continuous dosing scheme
  • Jul 29, 2013: Motor Protein Revs Up Cell Division
  • Jun 06, 2013: Leukemia & Lymphoma Society Honors Ohi’s Research
  • Jan 31, 2013: Tekmira Announces Publication Of Data On LNP Technology In Journal Cancer Discovery
  • Jan 30, 2013: Alnylam And Collaborators Publish Results From Phase I Clinical Trial And Extension Study With ALN-VSP For Treatment Of Liver Cancer
  • Dec 05, 2012: 4SC Reports Positive Data From Clinical Phase I Trial With 4SC-205 In Cancer Patients And Initiates Study Amendment
  • Jun 04, 2012: Alnylam Presents Results From Phase I Extension Study Of ALN-VSP At ASCO 2012 Annual Meeting
  • Mar 14, 2012: Tekmira Provides Update On Progress In USPTO Patent Interference Proceedings Related To Alnylam's ALN-VSP
  • Aug 01, 2011: Alnylam Completes Phase I Trial Of ALN-VSP In Liver Cancer
  • Jun 04, 2011: Alnylam Presents Phase I Data For ALN-VSP At American Society Of Clinical Oncology Meeting
  • May 18, 2011: Alnylam's ALN-VSP Abstract Published By American Society Of Clinical Oncology
  • Mar 31, 2011: Alnylam Completes Enrollment In ALN-VSP Phase I Clinical Trial
  • Jan 04, 2011: Alnylam Reports Positive Data From ALN-VSP Phase I Liver Cancer Trial
  • Nov 10, 2010: Alnylam Presents Additional Interim Phase I Data For ALN-VSP For Treatment Of Liver Cancer
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
  • List of Tables
  • Number of Products under Development by Stage of Development, H2 2018
  • Number of Products under Development by Therapy Areas, H2 2018
  • Number of Products under Development by Indication, H2 2018
  • Number of Products under Development by Companies, H2 2018
  • Products under Development by Companies, H2 2018
  • Products under Development by Companies, H2 2018 (Contd..1), H2 2018
  • Number of Products under Investigation by Universities/Institutes, H2 2018
  • Products under Investigation by Universities/Institutes, H2 2018
  • Number of Products by Stage and Mechanism of Actions, H2 2018
  • Number of Products by Stage and Route of Administration, H2 2018
  • Number of Products by Stage and Molecule Type, H2 2018
  • Pipeline by 4SC AG, H2 2018
  • Pipeline by Alnylam Pharmaceuticals Inc, H2 2018
  • Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2018
  • Pipeline by Merck & Co Inc, H2 2018
  • Dormant Products, H2 2018
  • Dormant Products, H2 2018 (Contd..1), H2 2018
  • Dormant Products, H2 2018 (Contd..2), H2 2018
  • Discontinued Products, H2 2018
  • List of Figures
  • Number of Products under Development by Stage of Development, H2 2018
  • Number of Products under Development by Top 10 Indications, H2 2018
  • Number of Products by Stage and Mechanism of Actions, H2 2018
  • Number of Products by Routes of Administration, H2 2018
  • Number of Products by Stage and Routes of Administration, H2 2018
  • Number of Products by Molecule Types, H2 2018
  • Number of Products by Stage and Molecule Types, H2 2018

Keywords
;